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The objective of this study was to determine whether polysomnographic 
rapid eye movement (REM) sleep abnormalities and cortisol response to 
the dcxamcthasone suppression test (DST) differentiate between 
schizophrenic patients with and without a history of suicidal behaviour. We 
assessed a sample of 96 schizophrenic in-patients at  the end of a 2-week 
medication-free period with the DST, polysomnography, and an extensive 
clinical assessment battery. Patients exhibiting suicidal behaviour were 
significantly more likely to have increased total REM time and increased 
total REM activity. We found no significant relationship between suicidal 
bchaviour and DST non-suppression. This study confirms a previous finding 
suggesting an association between REM sleep abnormalities and suicidal 
bchaviour in Schizophrenia. It is postulated that this observed association 
may be related to serotonergic dysfunction in schizophrenia. 
introduction 
Suicidal behaviour is a significant complication 
of schizophrenic illness. Approximately 50% of 
schizophrenic patients seriously consider or attempt 
suicide, and approximately 10% eventually succeed 
(1). Numerous clinical predictors of suicidal behav- 
iour in schizophrenic patients have been described, 
including young age, early stage of illness, sub- 
stance abuse, college education, multiple episodes 
of psychosis, living alone, previous suicide attempts, 
depression/hopelessness, and stress (2-8). Recent 
research in the field has focused on the neuro- 
biological substrates of suicidal behaviour in schizo- 
phrenia; as yet, this area remains largely undefined. 
Investigators have sought to draw lessons from 
the substantial body of research conducted on 
the pathophysiology of suicidal behaviour in major 
depression. Studies of cortisol secretion following 
administration of dexamethasone suggest that 40- 
50% of patients with major depression exhibit 
cortisol non-suppression (9), and that cortisol non- 
suppression is significantly more frequent in 
depressed suicidal patients than in depressed non- 
suicidal patients (9). Suicidal behaviour in patients 
with major depression has also been associated 
with sleep abnormalities (10). Sabo et al. studied a 
group of patients with depression and found that, 
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compared to non-attempters, suicide attempters 
exhibited increased sleep latency, decreased sleep 
efficiency, increased total REM time and increased 
REM activity. 
Although cortisol non-suppression of the DST 
and REM sleep abnormalities were originally 
considered to be abnormalities specific to major 
depressive disorder, recent research has clearly 
documented both types of abnormalities in a 
substantial proportion of schizophrenic patients 
(11, 12). Reports of an association between both 
REM sleep and DST abnormalities and suicidal 
behaviour in schizophrenia have recently been 
published (13,14). Keshavan et al. studied a sample 
of 19 schizophrenic subjects and reported that 
patients exhibiting suicidal behaviour had signifi- 
cantly increased overall REM activity and REM 
time (13). Jones et al. found that non-suppression 
of the DST may be related to suicidal behaviour in 
a sample of 57 schizophrenics; specifically, non- 
suppression of the DST differentiated suicide 
attempters from non-attempters (14). While these 
findings are obviously significant, they are of a 
preliminary nature. The aim of the present study 
was to evaluate the relationship between REM 
sleep abnormalities, DST response and suicidal 
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behaviour in a large sample of schizophrenic 
patients. 
Material and methods 
Subjects 
The study sample consisted of 96 patients who were 
admitted to the Schizophrenia Program at the 
University of Michigan. All of the patients received 
an extensive diagnostic evaluation, including a 
structured interview using the Schedule for Schizo- 
phrenia and Affective Disorders (SADS) (1S), 
and fulfilled both Research Diagnostic Criteria 
(RDC) (16) and DSM-III-R (17) criteria for schizo- 
phrenia. Patients with any medical condition known 
to interfere with a valid DST (9), and with any 
known ongoing drug or alcohol use were excluded 
from the study. All patients were medication-free 
for a minimum of 2 weeks, and none of them had 
received depot neuroleptics in the preceding 6 
months. The mean age (k SD) of all patients was 
29 k 9.2 years, and the sample consisted of 66 male 
and 30 female subjects. 
At medication-free baseline, all patients were 
rated on the 18-item Brief Psychiatric Rating Scale 
(BPRS) (18), the Scale for the Assessment of 
Negative Symptoms (SANS) (19) and the 17-item 
Hamilton Depression Rating Scale (HDRS) (20). 
Global severity was assessed by means of the 18- 
item BPRS total score. Positive symptom severity 
was assessed as the sum of the following four BPRS 
items: conceptual disorganization, suspiciousness, 
hallucinatory behaviour and unusual thought con- 
tent (21). Negative symptoms were quantified by 
the SANS sum of global scores. Other relevant 
sociodemographic and clinical variables used to 
characterize the sample included full-scale IQ, age 
at first hospitalization, and number of years of 
education. 
Methods 
Lifetime history of suicidal behaviour was obtained 
from a review of the clinical and research records 
of each patient by a rater (C.F.L.) who was blind 
to the DST and sleep data. Assessment involved 
extensive chart review, and review of the SADS 
interview and 1-year €allow-up data. Suicidal 
behaviour was defined on a scale which ranged 
from 0 to 2, where 0 denoted patients with no 
suicidal ideation or attempts (1-2 on SADS item 
no. 246), 1 denoted patients with suicidal ideation 
(3-4 on SADS item no. 246) and 2 denoted patients 
with suicide attempts (5-7 on SADS item no. 246); 
SADS ratings were corroborated by case records 
from the clinical charts. 
A 1-mg DST (9) was performed at baseline. 
Blood samples for post-dexamethasone cortisol 
levels were obtained at 16.00 and 23.00 hours, and 
the maximum cortisol levels were used for analysis. 
Cortisol levels were assayed by Murphy’s competi- 
tive protein-binding method (22). Maximal post- 
dexamethasone cortisol levels greater than S yg 
dl-’ have been shown to be indicative of non- 
suppression (9). Details of the DST methodology 
are described in Tandon et al. (12). Variables 
utilized for analysis included (a) maximal post- 
dexamethasone cortisol levels and (b) status as 
DST non-suppressor or suppressor. 
Two-night polysomnography was conducted in 
the patient’s hospital beds as described by Tandon 
et al. (11). The first night was used to exclude any 
underlying sleep abnormalities and the second 
night was used for data analysis. Patients were 
assessed for primary sleep disorders by means of 
questionnaires, and were excluded from the study 
if such abnormalities were noted. Manually derived 
sleep measures were obtained by technicians (who 
were blind to the clinical data on sleep) at 60-s 
intervals using the criteria of Rechstaffen and Kales 
(23). Relevant sleep measures used for analysis 
included sleep latency, total number of minutes 
asleep, time and percentage of sleep spent in Stages 
1 to 4 NREM and REM, and several REM meas- 
ures, including REM latency, activity and density. 
Data analysis 
The relationship between suicidal behaviour and 
sleep, clinical and DST data was evaluated 
by Kendall’s rank-correlation analysis. Stepwise 
regression between these variables was then per- 
formed in order to identify predictors of suicidal 
behaviour while controlling for other variables. 
Suicidal behaviour was the dependent variable, and 
clinical variables and sleep and DST data were the 
independent variables. 
Results 
There were 36 patients in group 1 (no suicidal 
ideatiodattempts), 38 patients in group 2 (suicidal 
ideation but no attempts) and 22 patients in group 
3 (suicidal attempts). Patients who exhibited 
suicidal behaviour had increased total REM time 
(Y = 0.40; P < 0.001) and increased REM activity 
(P<O.OS) (Fig. 1). However, no correlation was 
found between suicidal behaviour and proportion 
of slow-wave sleep (SWS), or between suicidal 
behaviour and REM latency, neither was there 
any significant correlation between baseline post- 
dexamethasone cortisol levels and suicidal behav- 
iour (Table 1). 
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Fig. I. Suicidal behaviour and total REM time in schizophrenia; 
n = 78. Mean values * SD are shown. 
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When the group of suicide attempters was 
divided into those who had made an attempt in the 
previous 6 months (n  = 6) and those who had made 
no attempts in the previous 6 months ( n  = 16), no 
difference in any sleep measure or in DST data was 
noted. Furthermore, when this group of 22 suicide 
attempters was divided into those with a history of 
a violent suicide attempt (n  =5) and those with no 
such history (n  = 17), no difference in sleep or DST 
findings was observed. 
There was a trend for patients who exhibited 
suicidal behaviour to be of lower age, male and 
to have received a higher level of education. Posi- 
tive and negative symptoms were not predictors of 
suicidal behaviour, but HRSD scores were cor- 
related with suicidal behaviour. 
On stepwise regression analysis, two variables 
emerged as significant predictors of suicidal behav- 
iour, namely total REM sleep (Y = 0.40; P< 0.001) 
and patient gender (r=0.50; P< 0.001). Together, 
these two variables accounted for 25% of the total 
variance in suicidal behaviour. 
Discussion 
This study found no significant correlation between 
suicidal behaviour and post-dexamethasone sup- 
pression levels. This result is in contrast to that of 
Jones et al. (14), and is particularly striking given 
the high rate of dexamethasone non-suppression 
(40%) observed in this sample of schizophrenic 
patients. DST non-suppression has been associated 
with shortened REM latency in depressive subjects 
(24), and it is salient that neither DST non- 
suppression nor decreased REM latency were 
found to be associated with lifetime suicidal behav- 
iour in the present study. This suggests that the 
mechanisms underlying DST non-suppression and 
shortened REM latency in schizophrenia may be 
state-related (25), and unrelated to suicidal behav- 
iour. Our observation of an association between 
suicidal behaviour and male gender, longer educa- 
tion and younger age is consistent with previous 
reports of clinical predictors of suicidal behaviour 
in schizophrenia. 
The main positive finding in this study is 
the significant association between total REM 
sleep time and suicidal behaviour. Total REM 
activity was also found to be significantly cor- 
related with suicidal behaviour, a finding that is 
consistent with previous studies of schizophrenia 
(13). These results are similar to the data for 
suicidal patients with major depression (10). It is 
noteworthy that depression severity scores as 
assessed by the HRSD did not correlate signifi- 
cantly with REM sleep abnormalities (11). The 
significant association between total REM sleep 
time and suicidal behaviour suggests that a com- 
mon mechanism may underlie both of these abnor- 
malities in schizophrenia. Although the precise 
nature of this common mechanism is unknown, 
reduced central nervous system (CNS) serotonergic 
function, as measured by 5-hydroxy indole-acetic 
acid (5HIAA) levels in the cerebrospinal fluid, is 
associated with suicidal behaviour in depression 
(10, 26, 27) and schizophrenia (13, 28). Since 
serotonergic neurones act to suppress REM sleep, 
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reduced serotonergic function in schizophrenia 
could explain the association between suicidal 
behaviour and REM time/activity observed in the 
present study. Serotonergic hypoactivity has been 
specifically implicated in violent suicide attempts 
(29, 30). However, we observed no significant 
difference between violent and non-violent suicide 
attempters in our sample of schizophrenic patients. 
It should be emphasized that schizophrenic ill- 
ness in general is not characterized by any abnor- 
mality of REM time or activity (11). However, 
within the group of schizophrenic patients, subjects 
with longer REM time and higher REM activity 
are more likely to exhibit lifetime suicidal behav- 
iour than those with shorter REM time and lower 
REM activity. Thus longer REM time and higher 
REM activity might be a marker of suicidal behav- 
iour in schizophrenia. However, this association 
does not appear to be specific to schizophrenia, as 
it has also been described in samples of depressed 
patients (10). 
The association between total REM sleep 
and activity and suicidal behaviour is somewhat 
surprising, given the fact that the sleep studies were 
conducted during a state of acute psychotic exacer- 
bation, while lifetime suicidal behaviour reflects a 
trait abnormality in schizophrenia. When we com- 
pared recent suicide attempters (attempts within 
the previous 6 months) with those with a lifetime 
history of suicide attempts but without a history 
of recent attempts, we observed no significant 
difference between the groups with regard to REM 
time or activity, or any sleep or DST findings. 
However, REM time and activity are relatively 
stable throughout a course of schizophrenic illness. 
Although they were assessed during a psychotic 
state, they may in fact reflect a stable trait feature, 
and this might explain the association between 
REM time and lifetime history of suicidality that 
we observed in our sample of schizophrenic 
patients. 
Caution must be exercised when relating possible 
state findings, such as sleep data, to trait aspects, 
such as lifetime history of suicidal behaviour. How- 
ever, its documentation in two separate sets of data 
suggests that it merits further study. 
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